These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 324624)

  • 1. Combination VM-26 and adriamycin for metastatic transitional cell carcinoma.
    Rodriguez LH; Johnson DE; Holoye PY; Samuels ML
    Cancer Treat Rep; 1977; 61(1):87-8. PubMed ID: 324624
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combination of adriamycin, VM 26, cyclophosphamide and prednisone in the treatment of hematosarcomas].
    Laurens A; Thevenot J; Charron D; Jorry F; Dumonchel P; Martola R
    Ann Med Interne (Paris); 1977 May; 128(5):493-6. PubMed ID: 334012
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
    Qazi R; Elson P; Khandekar JD
    Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of VM-26 as a single agent in the treatment of transitional cell carcinoma of the urinary tract].
    Aso Y; Ushiyama T; Suzuki K; Tajima A; Naide Y; Ohshima S; Matsuura O; Fukushima M; Ota K; Ono Y
    Nihon Gan Chiryo Gakkai Shi; 1988 May; 23(5):1046-51. PubMed ID: 3418215
    [No Abstract]   [Full Text] [Related]  

  • 5. Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.
    Oishi N; Berenberg J; Blumenstein BA; Johnson K; Rivkin SE; Bukowski RM; O'Bryan RM; Stephens RL; Quagliana J; Saiers JH
    Cancer Treat Rep; 1987 Dec; 71(12):1307-8. PubMed ID: 3690547
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26.
    Gad-el-Mawla NM; Muggia FM; Hamza MR; El-Morsi B; Sherif M; Mansour MA; Khafagy M; El-Sebai IT
    Cancer Treat Rep; 1978 Jul; 62(7):993-6. PubMed ID: 99234
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
    Panduro J; Hansen M; Hansen HH
    Cancer Treat Rep; 1981; 65(7-8):703-4. PubMed ID: 7248987
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II trial of VM-26 in patients with metastatic malignant melanoma.
    Bellet RE; Catalno RB; Mastrangelo MJ; Berd D; Koons LS
    Cancer Treat Rep; 1978 Mar; 62(3):445-7. PubMed ID: 348313
    [No Abstract]   [Full Text] [Related]  

  • 10. [Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial].
    Pouillart P; Mathé G; Poisson M; Buge A; Huguenin P; Gautier H; Morin P; Thy HT; Lheritier J; Parrot R
    Nouv Presse Med; 1976 Jun; 5(25):1571-6. PubMed ID: 778798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined chemotherapy in the management of metastatic bladder cancer.
    Garcia-Giralt E; Auvert J; Lachand AT; Botto H; Abbou C; Hannoun M; Pouillart P; Palangie T; Jouve M; Morin P
    Br J Urol; 1981 Aug; 53(4):318-9. PubMed ID: 7260545
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II study of VM-26 in adult malignancies.
    Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
    Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of VM-26 as a single agent in the treatment of renal carcinoma.
    Hire EA; Samson MK; Fraile RJ; Baker LH
    Cancer Clin Trials; 1979; 2(4):293-5. PubMed ID: 394865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adriamycin, VM 26, cyclophosphamide and prednisone (AVmCP) combination in the therapy of disseminated lymphoreticulosarcoma (Stages or topographical forms III and IV].
    Misset JL; Pouillart P; Amiel JL; Schwarzenberg L; Hayat M; de Vassal F; Musset M; Belpomme D; Jasmin C; Albahary C; Depierre R; Mathé G
    Nouv Presse Med; 1975 Dec; 4(44):3117-20. PubMed ID: 768904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of small cell bronchogenic carcinoma with VM-26.
    Woods RL; Fox RM; Tattersall MH
    Cancer Treat Rep; 1979; 63(11-12):2011-3. PubMed ID: 230897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of inoperable glioblastomas using a combination of adriamycin, VM 26 and CCNU].
    Pouillart P; Mathé G; Huguenin P; M'orin P; Poisson M; Buge A; Palangie T; Parrot R
    Bull Cancer; 1977; 64(1):125-36. PubMed ID: 193597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary evaluation of VM-26: a new epipodophyllotoxin derivative, in the treatment of urogenital tumours.
    Pavone-Macaluso M; Caramia G; Rizzo FP; Messana V
    Eur Urol; 1975; 1(1):53-6. PubMed ID: 786645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of malignant gliomas in adults using a combination of adriamycine, VM 26 and CCNU: results of a type II trial.
    Pouillart P; Mathe G; Thy TH; Lheritier J; Poisson M; Huguenin P; Gautier H; Morin P; Parrot R
    Eur J Cancer (1965); 1977; 13(4-5):419-24. PubMed ID: 326555
    [No Abstract]   [Full Text] [Related]  

  • 19. Teniposide in epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group.
    Muss H; Bundy BN; DiSaia PJ; Twiggs LB
    Cancer Treat Rep; 1986 Oct; 70(10):1231-2. PubMed ID: 3530450
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II study of 5-fluorouracil and adriamycin in transitional cell carcinoma of the urinary tract.
    Martino S; Samal B; Al-Sarraf M
    Cancer Treat Rep; 1980 Jan; 64(1):161-3. PubMed ID: 7379051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.